文献速递淋巴瘤造血干细胞移植与细胞治疗

CD19 CAR-T细胞培养中PD-1表达、mRNA水平及杀伤活性变化

[PD-1 expression, mRNA level and cytotoxicity changes in CD19CAR-T cells].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2019-01-01

研究以6例PD-1高表达淋巴瘤患者和6例健康志愿者的外周血T细胞制备CD19 CAR-T细胞,观察培养过程中PD-1蛋白、mRNA及杀伤活性变化。结果显示高PD-1来源CAR-T杀伤活性较低,联合PD-1抑制剂可恢复;与淋巴瘤细胞接触后PD-1蛋白随培养时间增高,但mRNA水平各组无差异。

要点

  • 高PD-1来源CAR-T对淋巴瘤细胞杀伤活性低于健康志愿者来源CAR-T(P<0.001)。
  • 联合PD-1抑制剂可恢复高PD-1来源CAR-T的杀伤活性至健康志愿者水平(P>0.05)。
  • 与淋巴瘤细胞接触后CAR-T的PD-1蛋白随培养时间增高(P<0.001),PD-1抑制剂可拮抗。

核心结论

  • PD-1高表达T细胞来源的CAR-T细胞与肿瘤细胞接触后,其PD-1蛋白表达随培养时间延长而增高。
  • 包括PD-1抑制剂在内,不能改变各组CAR-T细胞PD-1 mRNA的表达水平。

研究设计与样本

  • 研究纳入6例外周血PD-1高表达恶性淋巴瘤患者和6例健康志愿者的外周血T细胞作为CAR-T细胞来源。
  • 采用流式细胞术检测PD-1蛋白表达,PCR法检测PD-1 mRNA水平,CCK-8法检测细胞增殖,LDH法检测细胞杀伤活性。

主要发现

  • PD-1高表达患者T细胞来源CD19 CAR-T与志愿者T细胞来源者转染率无差异(P>0.05)。
  • PD-1高表达T细胞来源CAR-T联合PD-1抑制剂与否及健康志愿者CAR-T之间,细胞增殖差异无统计学意义(P>0.05)。
  • PD-1高表达T细胞与CAR-T细胞对淋巴瘤细胞株杀伤活性低于联合PD-1抑制剂及志愿者CAR-T细胞(P<0.001)。
  • PD-1高表达T细胞来源CAR-T联合PD-1抑制剂与健康志愿者CAR-T细胞间杀伤活性差异无统计学意义(P>0.05)。
  • 各组细胞培养过程中PD-1表达及PD-1 mRNA变化差异均无统计学意义(P>0.05)。

临床怎么用

  • 对PD-1高表达淋巴瘤患者来源的CAR-T细胞,联合PD-1抑制剂可能改善其杀伤活性。
  • 培养过程中监测PD-1蛋白表达变化有助于评估CAR-T细胞功能状态。

局限性

  • 研究样本量较小,仅纳入6例患者和6例健康志愿者。
  • 研究为体外实验,结果需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To observe the changes of PD-1 expression, mRNA level and cytotoxic activity of CD19 CAR-T cells during the culture process of CAR-T cells. Methods: The peripheral blood T cells of 6 lymphoma patients with high expression of PD-1 and 6 healthy volunteers were the source of CAR-T cells. The expression of PD-1 was analyzed by flow cytometry. The mRNA level of PD-1 was analyzed by PCR. The cell proliferation was analyzed by CCK-8 assay. The cytotoxicity was analyzed by LDH assay. Results: ①The transfection efficiency of high PD-1 expression T cells and healthy volunteer T cells were as the same (P>0.05) . ②The cell proliferation capacity of CD19 CAR-T cells from high PD-1 expression T cells or healthy volunteer T cells, with or without PD-1 inhibitor were as the same (P>0.05) . ③The cytotoxicity to lymphoma cells of high PD-1 expression T cells and CAR-T cells were lower than that of these two T cells combined with PD-1 inhibitor and the CAR-T cells from healthy volunteer T cells (P<0.001) . There was no difference of the cytotoxicity between the CAR-T cells from high PD-1 expression T cells combined with PD-1 inhibitor and the CAR-T cells from healthy volunteer (P>0.05) . ④There was no difference of the expression of PD-1 in all CAR-T cell groups during the culture process (P>0.05) . There was no difference of mRNA level of PD-1 in all groups during the culture process (P>0.05) . ⑤The PD-1 expression of CAR-T cells increased by the time of culture after contacting with lymphoma cells (P<0.001) . The PD-1 inhibitors could antagonize this effect. There was no difference of mRNA level of PD-1 in all groups after contacting with lymphoma cells (P>0.05) . Conclusion: The PD-1 expression of CAR-T cells from high PD-1 expression T cells increased by the time of culture after contacting with lymphoma cells. However, the mRNA level of PD-1 of all groups did not change, even if PD-1 inhibitor was applied. 目的: 探讨CD19 CAR-T细胞培养过程中其PD-1蛋白、mRNA水平及细胞杀伤活性变化。 方法: 收集6例外周血PD-1高表达恶性淋巴瘤患者、6例健康志愿者的外周血T细胞,作为CAR-T培养的T细胞来源。流式细胞术检测PD-1蛋白表达、PCR法检测PD-1 mRNA水平,CCK-8法检测细胞增殖,LDH法检测细胞杀伤活性。 结果: ①PD-1高表达患者T细胞来源CD19 CAR-T细胞,与志愿者T细胞来源者相比,转染率无差异(P>0.05);②PD-1高表达T细胞来源CAR-T细胞与PD-1抑制剂联合与否,以及健康志愿者CAR-T之间,细胞增殖差异无统计学意义(P>0.05);③PD-1高表达T细胞与CAR-T细胞对淋巴瘤细胞株杀伤活性,低于二者联合PD-1抑制剂及志愿者CAR-T细胞(P<0.001),而PD-1高表达T细胞来源CAR-T细胞联合PD-1抑制剂与健康志愿者CAR-T细胞间差异无统计学意义(P>0.05);④各组细胞培养过程中PD-1表达均下降,差异无统计学意义(P>0.05),但各组细胞培养过程中,PD-1 mRNA的变化差异无统计学意义(P>0.05);⑤PD-1高表达T细胞来源CAR-T收获后,与PD-1抑制剂共培养与否,其PD-1表达差异无统计学意义(P>0.05),但CAR-T与淋巴瘤细胞株接触后,其PD-1表达随培养时间延长而增高,加入PD-1抑制剂可拮抗该作用;各组间PD-1 mRNA的变化差异无统计学意义(P>0.05)。 结论: PD-1高表达T细胞来源CAR-T细胞与肿瘤细胞接触后,其PD-1表达随培养时间延长而增高;而包括PD-1抑制剂在内,不能改变其PD-1 mRNA的表达。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Pu YD, Wang J, Deng Q, et al. [PD-1 expression, mRNA level and cytotoxicity changes in CD19CAR-T cells]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31648479. doi:10.3760/cma.j.issn.0253-2727.2019.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。